CoChat

Comparison of the effects on glycaemic control and β‐cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel‐group trial (the CONFIDENCE study)

Open access
Xu, W., Bi, Y., Sun, Z., Li, J., Guo, L., Yang, T., Wu, G., Shi, L., Feng, Z., Qiu, L., Li, Q., Guo, X., Luo, Z., Lu, J., Shan, Z., Yang, W., Ji, Q., Yan, L., Li, H., Yu, X., Li, S., Zhou, Z., Lv, X., Liang, Z., Lin, S., Zeng, L., Yan, J., Ji, L., Weng, J. · 2015 · Journal of Internal Medicine
Cited by 58

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Objective: Progressive β‐cell dysfunction hinders the maintenance of glycaemic control in type 2 diabetes, but comparative data on β‐cell‐protective therapies are lacking in the early stage of type 2 diabetes. Here we evaluated the comparative glycaemic efficacy and impact on β‐cell function of three antihyperglycaemic agents that have a β‐cell‐protective effect, exenatide, insulin and pioglitazone, in newly diagnosed patients with type 2 diabetes. Design and methods: In this 48‐week, multicentre, parallel‐group study, 416 patients newly diagnosed with type 2 diabetes were randomly assigned 1 : 1 : 1 to receive exenatide, insulin or pioglitazone. The primary end‐point was the change in glycosylated haemoglobin (HbA1c) from baseline. Secondary end‐points included effects on weight, blood pressure, lipid profiles and β‐cell function assessed by homeostasis model assessment, fasting proinsulin:insulin (PI/I), disposition index (DI) and acute insulin response (AIR). Results: At week 48, mean [95% confidence interval (CI)] HbA 1c changes from baseline were −1.8% (−1.55% to −2.05%) with exenatide, −1.7% (−1.52% to −1.96%) with insulin and −1.5% (−1.23% to −1.71%) with pioglitazone. Treatment differences were −0.20% (95% CI −0.46% to 0.06%) for exenatide versus insulin (P = 0.185), and −0.37% (95% CI −0.63% to −0.12%) for exenatide versus pioglitazone (P = 0.002). Significant improvements from baseline in AIR, PI/I and DI were observed with all treatments, with the greatest improvements in DI, as well as weight, blood pressure and lipid profile, observed with exenatide. Conclusions: All three agents showed efficacy regarding glycaemic control and metabolic benefits; however, exenatide showed the greatest efficacy. β‐cell function improved in all treatment groups; hence, early initiation of β‐cell‐protective therapy may halt the decline in β‐cell function in type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/joim.12293

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 58

Metadata

Authors
Xu, W., Bi, Y., Sun, Z., Li, J., Guo, L., Yang, T., Wu, G., Shi, L., Feng, Z., Qiu, L., Li, Q., Guo, X., Luo, Z., Lu, J., Shan, Z., Yang, W., Ji, Q., Yan, L., Li, H., Yu, X., Li, S., Zhou, Z., Lv, X., Liang, Z., Lin, S., Zeng, L., Yan, J., Ji, L., & Weng, J.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
2014-08-05
Volume
277
Issue
1
Pages
137-150
ISSN
  • 0954-6820 (ISSN-L)
  • 1365-2796
OpenAlex
W2069665789
Cited by
58
References
10
FWCI
5.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.